BAJAJ BROKING
Biocon posted a strong Q4 FY25 with consolidated net profit rising 153% YoY to Rs.344 crore. Revenue from operations increased 12% to Rs.4,454 crore. The board approved a final dividend of Rs.0.50 per share for FY25.
Biocon delivered a robust Q4 FY25 performance, driven by its biosimilars and generics businesses. Consolidated net profit rose sharply by 153% year-on-year to Rs.344 crore, up from Rs.136 crore in Q4 FY24. Revenue from operations reached Rs.4,454 crore, reflecting a 12% increase over the same quarter last year.
Group core EBITDA stood at Rs.1,363 crore, up 16% YoY, with a core operating margin of 31%. Overall EBITDA was reported at Rs.1,115 crore, also up 16%, with a margin of 25%. The company declared a final dividend of Rs.0.50 per share, representing 10% of the face value.
Q4 FY25 net profit surged 153% YoY to Rs.344 crore from Rs.136 crore.
Revenue from operations rose 12% YoY to Rs.4,454 crore.
Core EBITDA for the quarter stood at Rs.1,363 crore; margin at 31%.
Final dividend of Rs.0.50 per share recommended for FY25.
Board approved fund-raising of up to Rs.4,500 crore through multiple routes.
Biocon marked its entry into the GLP-1 therapy segment with the UK launch of Liraglutide, expanding its therapeutic reach. Its biosimilars segment remained a global growth driver, with four products crossing the $200 million mark in sales. Syngene's acquisition of a biologics manufacturing facility in the US further strengthens its capabilities.
Looking ahead, Biocon aims to scale its GLP-1 portfolio, expand into new markets, and improve API business efficiency with new capacities and cost optimisation in FY26.
The biopharma sector is poised for innovation-led growth, driven by rising biosimilar adoption, new molecule launches, and healthcare demand. Biocon’s strategic investments in biologics, global manufacturing, and differentiated generics position it favourably to capitalise on industry tailwinds and global market expansion.
Metric | Q4 FY25 | Q4 FY24 | FY25 (Est.) | FY24 (Est.) |
Revenue from operations (Rs. Cr) | 4,454 | 3,975 | 16,470 | 15,695 |
Net profit (Rs. Cr) | 344 | 136 | 1,013 | 1,022 |
Core EBITDA (Rs. Cr) | 1,363 | 1,175 | – | – |
Core operating margin | 31% | – | – | – |
Dividend per share (Rs.) | 0.50 | – | 0.50 | – |
Fund-raising approved | – | – | Rs.4,500 Cr | – |
Source: Biocon Ltd – Board Meeting Outcome and Audited Q4 FY25 Financial Results
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading